ARCT News and Press, Arcturus Therapeutics Ltd. From 06/01/23

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...

2023-05-12 17:45:30 ET Gainers: GSI Technology ( GSIT ) +16% . Telos ( TLS ) +8% . Arcturus Therapeutics Holdings ( ARCT ) +5% . Atara Biotherapeutics ( ATRA ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Zapp Electric Ve...

2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...

2023-05-11 08:21:38 ET Arcturus Therapeutics ( NASDAQ: ARCT ) added ~3% pre-market Thursday after H.C. Wainwright upgraded the biotech to Buy from Neutral, raising its price target to $51 from $19 per share on the potential of its COVID-19 vaccine ARCT-154. In November, Arct...

2023-05-09 22:05:23 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Neda Safarzadeh – Vice President, Head-Investor Relations, Public Relations and Marketing Joseph Payne – Presi...

2023-05-09 16:05:22 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q1 GAAP EPS of $1.87 beats by $1.46 . Revenue of $80.29M (+1432.3% Y/Y) beats by $30.83M . For further details see: Arcturus Therapeutics GAAP EPS of $1.87 beats by $1.46, revenu...

New Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan, leading to potential approval in 2023 $23.6 Million advanced for the manufacturing and supply of ARCT-154 ARCT-032 Phase 1 enrollment and administration completed successfully;...

2023-05-08 14:50:16 ET Arcturus Therapeutics ( NASDAQ: ARCT ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $49.46M (vs. $5.24M last year). Over the last ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare disease...

2023-04-11 13:03:15 ET Summary Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing valuable experience to the company's pipeline deve...